Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 379-384

  Palmer, J M ^a   Chen, B J ^a   Deoliveira, D ^a   Le, N D ^a   Chao, N J ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Graft versushost disease; Rapamycin; Regulatory T cells

Indexed keywords

RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; SPLEEN CELL; SURVIVAL RATE; TARGET ORGAN;

ANIMALS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; INTESTINES; LIVER; MICE; MICE, INBRED BALB C; SIROLIMUS; SKIN; T-LYMPHOCYTES, REGULATORY;

EID: 76749087402     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.140     Document Type: Article

References (29)

1. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia- Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines. J Immunol 1998; 160: 5355-5365.
2. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graftversus- host disease. Br J Haematol 2005; 130: 409-417.
3. Antin JH, Cutler C. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplantation 2004; 34: 471-476.
4. Chen BJ, Morris R, Chao NJ. Graft-Versus-Host Disease Prevention by Rapamycin: Cellular Mechanisms. Biol Blood Marrow Transplant 2000; 6: 529-536.
5. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018.
6. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graftversus- host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601-1605.
7. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108-3114.
8. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006; 177: 944-949.
9. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2775-2784.
10. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031.
11. Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-4748.
12. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo M-G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of Both Healthy Subjects and Type 1 Diabetic Patients. J Immunol 2006; 177: 8338-8347.
13. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-462.
14. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320-329.
15. Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220-2226.
16. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 107: 3300-3307.
17. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation. J Exp Med 2002; 196: 389-399.
18. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107: 1717-1723.
19. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 995-1009.
20. Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Hematol 2006; 28: 382-390.
21. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007; 98: 874-881.
22. Bamias G, Okazawa A, Rivera-Nieves J, Arseneau KO, De La Rue SA, Pizarro TT et al. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J Immunol 2007; 178: 1809-1818.
23. Keever-Taylor CA, Browning M, Johnson B, Truitt R, Bredeson C, Behn B et al. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivoexpanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007; 9: 144-157.
24. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
25. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
26. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087.
27. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes withGMCSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101
28. Nguyen VH, Zeiser R, daSilva DL, Chang DS, Beilhack A, Contag CH et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109: 2649-2656.
29. Kang SG, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin a metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol 2007; 179: 3724-3733.